Literature DB >> 26054682

FOXP1 and SPINK1 reflect the risk of cirrhosis progression to HCC with HBV infection.

Fei Li1, Ting Liu1, Chun-Yang Xiao1, Jing-Xia Yu1, Lun-Gen Lu1, Ming-Yi Xu2.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) deriving from cirrhosis with HBV infection harbors higher morbidity and poor prognosis. The diagnosis of HCC at its early stage is essential for improving the effect of treatment and survival rate of patients.
METHOD: Affymetrix GeneChip was practiced to establish gene expression profile and significance analysis of microarray (SAM) as well as prediction analysis of microarray (PAM) was utilized to screen candidate marker genes in tissue of carcinoma and para-cancerous with cirrhosis from 15 hepatitis B virus (HBV) related HCC patients. RESULT: Total 497 differential genes were selected by microarray (fold change >2; P value<0.01). Then 162 significant genes were determined by SAM (fold change -1.46 to 1.28). A number of 8-genes showing "poor risk signature" was validated with threshold of 6.2, which was associated with cirrhosis progressing to HCC. Only 3 down-regulated and 2 up-regulated predictor genes had statistical difference in HCC and cirrhosis groups by RT-PCR (P value<0.01). Forkhead box protein 1 (FOXP1) and serine protease inhibitor Kazal-type 1 (SPINK1) proteins were found significantly increased in carcinoma tissues than para-cancerous cirrhotic tissues by IH and WB.
CONCLUSION: Over-expression of FOXP1 and SPINK1 may participate in the carcinogenesis of HBV related cirrhosis. They could use as potential biomarkers for diagnosing early HCC.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cirrhosis; Forkhead box protein 1 (FOXP1); Hepatitis B virus (HBV); Hepatocellular carcinoma (HCC); Serine protease inhibitor Kazal-type 1 (SPINK1)

Mesh:

Substances:

Year:  2015        PMID: 26054682     DOI: 10.1016/j.biopha.2015.04.006

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

1.  Robust transcriptional tumor signatures applicable to both formalin-fixed paraffin-embedded and fresh-frozen samples.

Authors:  Rou Chen; Qingzhou Guan; Jun Cheng; Jun He; Huaping Liu; Hao Cai; Guini Hong; Jiahui Zhang; Na Li; Lu Ao; Zheng Guo
Journal:  Oncotarget       Date:  2017-01-24

2.  Hepatitis B Virus X Protein-Induced Serine Protease Inhibitor Kazal Type 1 Is Associated with the Progression of HBV-Related Diseases.

Authors:  Chengliang Zhu; Huan Han; Jie Li; Limin Xu; Fang Liu; Kailang Wu; Xinghui Liu
Journal:  Biomed Res Int       Date:  2019-05-22       Impact factor: 3.411

3.  A novel diagnostic four-gene signature for hepatocellular carcinoma based on artificial neural network: Development, validation, and drug screening.

Authors:  Min Chen; Guang-Bo Wu; Zhi-Wen Xie; Dan-Li Shi; Meng Luo
Journal:  Front Genet       Date:  2022-09-28       Impact factor: 4.772

4.  Downregulation of FOXP1 Inhibits Cell Proliferation in Hepatocellular Carcinoma by Inducing G1/S Phase Cell Cycle Arrest.

Authors:  Xin Wang; Ji Sun; Meiling Cui; Fangyu Zhao; Chao Ge; Taoyang Chen; Ming Yao; Jinjun Li
Journal:  Int J Mol Sci       Date:  2016-09-08       Impact factor: 5.923

5.  Upregulation of FOXP1 is a new independent unfavorable prognosticator and a specific predictor of lymphatic dissemination in cutaneous melanoma patients.

Authors:  Piotr Donizy; Konrad Pagacz; Jakub Marczuk; Wojciech Fendler; Adam Maciejczyk; Agnieszka Halon; Rafal Matkowski
Journal:  Onco Targets Ther       Date:  2018-03-14       Impact factor: 4.147

6.  Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance.

Authors:  Fei Chen; Qilai Long; Da Fu; Dexiang Zhu; Yan Ji; Liu Han; Boyi Zhang; Qixia Xu; Bingjie Liu; Yan Li; Shanshan Wu; Chen Yang; Min Qian; Jianmin Xu; Suling Liu; Liu Cao; Y Eugene Chin; Eric W-F Lam; Jean-Philippe Coppé; Yu Sun
Journal:  Nat Commun       Date:  2018-10-17       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.